Noeul Secures ₩4 Billion, 3-Year Supply Deal for Taiwan's Next-Gen 'MyLab BCM'

Noel aggressively targets Taiwan market with innovative AI blood diagnostic 'miLab™ BCM'... Launches global expansion. Noel, an AI-based blood and cancer diagnostic specialist, has signed a contract to supply its innovative AI blood diagnostic solution, 'miLab™ BCM', to Taiwan, effectively opening the door to the advanced medical market in Asia. This agreement is regarded as a significant milestone, marking the first global achievement of Noel's unparalleled technological capabilities. This mid-to-long-term partnership, involving the supply of products worth approximately 4 billion KRW (2.7 million USD) over the next three years, is expected to serve as a stepping stone for Noel to secure key strongholds in the Asian region and accelerate its expansion into the global market. Noel plans to gradually supply the new 'miLab™ BCM' product, focusing on major hospitals and diagnostic institutions within Taiwan, and use this as a foundation to solidify its presence in advanced global markets beyond Asia, including Europe and North America. Ahead of its official launch in December, 'miLab™ BCM' is an all-in-one AI diagnostic platform that implements complete blood count (CBC) and morphology-based abnormal cell detection in a single device. With just a small amount of whole blood, 5 microliters (μL), it automates the entire process from CBC measurement, smear and staining, and digital imaging to AI analysis, maximizing diagnostic efficiency and accuracy. Notably, it boasts unique technological prowess in precisely detecting even subtle abnormal cells such as immature granulocytes (IG) and blasts, which were difficult to detect with existing equipment, and is expected to make an innovative contribution to the early diagnosis and monitoring of blood diseases. In a recent joint performance evaluation with Asan Medical Center in Seoul, 'miLab™ BCM' recorded a high concordance with global standard equipment, and firmly demonstrated its technological reliability with an overwhelming concordance rate of over 95% in abnormal cell detection. This result showcases Noel's AI diagnostic technology performing excellently in real clinical settings. Lim Chan-yang, CEO of Noel, stated, "This Taiwan supply contract is a very important milestone, officially recognizing the competitiveness of Noel's AI-based blood diagnostic technology in the advanced Asian market. Starting with our entry into the Taiwan market, we will actively expand sales into advanced global markets such as Europe and North America to dramatically improve the company's profitability and are committed to providing innovative diagnostic solutions to medical sites worldwide." Meanwhile, based on its world-class healthcare system and infrastructure, Taiwan is actively promoting government-level policies to encourage the adoption of digital healthcare and AI technology, making it an optimal environment for innovative diagnostic devices like Noel's to successfully establish themselves. Noel's entry into the Taiwan market is expected to be a significant opportunity to further elevate the status of Korean technology in the global AI healthcare market.